Cingulate Therapeutics (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of Central Nervous System and Neurobiological Disorders. Currently, CTx is developing two products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The leadership team brings extensive expertise in ADHD, clinical trials, patient care, pharmaceutical development and new product commercialization.
CTx embraces innovation through cutting-edge technology, streamlined regulatory approach and demand for capital efficiency.
For decades, clinicians have sought to provide their ADHD patients with an ideal treatment that works quickly, provides appropriate duration and is safe and well tolerated. We aim to overcome this long-standing unmet need by providing new and exceptional treatment options for clinicians and patients.